Silver Grove Financial Group’s Corcept Therapeutics CORT Stock Holding History

Silver Grove Financial Group’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.5K	Buy	+121	New	+$7.31K	0.01%	872

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silver Grove Financial Group's CORT Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 121 shares worth $10.5K. The stake represents 0.01% of the portfolio and ranks #872 among its holdings.

422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Silver Grove Financial Group held 121 shares of Corcept Therapeutics worth $10.5K as of Q2 2026.
Corcept Therapeutics was a new Silver Grove Financial Group position in Q2 2026.
Corcept Therapeutics made up 0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #872 holding.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.